Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus, a randomized, open-label, multicenter phase 2 study Meeting Abstract


Authors: Hofmeister, C. C.; Chari, A.; Cohen, Y.; Spencer, A.; Voorhees, P. M.; Estell, J.; Venner, C. P.; Sandhu, I.; Jenner, M. W.; Williams, C.; Cavo, M.; Van De Donk, N. W. C. J.; Beksac, M.; Kuppens, S.; Bandekar, R.; Neff, T.; Heuck, C.; Qi, M.; Goldschmidt, H.; Landgren, O.
Abstract Title: Daratumumab monotherapy for patients with intermediate or high-risk smoldering multiple myeloma (SMM): Centaurus, a randomized, open-label, multicenter phase 2 study
Meeting Title: 59th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 130
Issue: Suppl. 1
Meeting Dates: 2017 Dec 9-12
Meeting Location: Atlanta, GA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2017-12-07
Language: English
ACCESSION: WOS:000432419401158
PROVIDER: wos
Notes: Meeting Abstract: 510 -- Source: Wos
MSK Authors
  1. Carl Ola Landgren
    175 Landgren